S
Suneil Jain
Researcher at Queen's University Belfast
Publications - 123
Citations - 8466
Suneil Jain is an academic researcher from Queen's University Belfast. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 30, co-authored 104 publications receiving 6628 citations. Previous affiliations of Suneil Jain include Belfast City Hospital & American Society of Clinical Oncology.
Papers
More filters
Journal ArticleDOI
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer.
Joaquin Mateo,Suzanne Carreira,Shahneen Sandhu,Susana Miranda,Helen Mossop,Raquel Perez-Lopez,Daniel Nava Rodrigues,Dan R. Robinson,Aurelius Omlin,Nina Tunariu,Gunther Boysen,Nuria Porta,Penny Flohr,Alexa Gillman,Ines Figueiredo,Claire Paulding,George Seed,Suneil Jain,Christy Ralph,Andrew Protheroe,Syed A. Hussain,Robert Jones,Tony Elliott,Ursula McGovern,Diletta Bianchini,Jane C. Goodall,Zafeiris Zafeiriou,Chris T. Williamson,Roberta Ferraldeschi,Ruth Riisnaes,Bernardette Ebbs,Gemma Fowler,Desamparados Roda,Wei Yuan,Yi-Mi Wu,Xuhong Cao,Rachel Brough,Helen Pemberton,Roger A'Hern,Amanda Swain,Lakshmi P. Kunju,Rosalind A. Eeles,Gerhardt Attard,Christopher J. Lord,Alan Ashworth,Mark A. Rubin,Karen E. Knudsen,Felix Y. Feng,Arul M. Chinnaiyan,Emma Hall,Johann S. de Bono +50 more
TL;DR: Treatment with the PARP inhibitor olaparib in patients whose prostate cancers were no longer responding to standard treatments and who had defects in DNA-repair genes led to a high response rate.
Journal ArticleDOI
Long-Term Follow-Up of a Large Active Surveillance Cohort of Patients With Prostate Cancer
Laurence Klotz,Laurence Klotz,Danny Vesprini,Danny Vesprini,Perakaa Sethukavalan,Perakaa Sethukavalan,Vibhuti Jethava,Vibhuti Jethava,Liying Zhang,Liying Zhang,Suneil Jain,Toshihiro Yamamoto,Toshihiro Yamamoto,Alexandre Mamedov,Alexandre Mamedov,Andrew Loblaw,Andrew Loblaw +16 more
TL;DR: Active surveillance for favorable-risk prostate cancer is feasible and seems safe in the 15-year time frame and the mortality rate is consistent with expected mortality in favorable- risk patients managed with initial definitive intervention.
Journal ArticleDOI
Gold nanoparticles as novel agents for cancer therapy
TL;DR: The field of nanotechnology with a focus on recent gold nanoparticle research which has led to early-phase clinical trials is introduced, and the pre-clinical evidence for gold nanoparticles as sensitisers with ionising radiation in vitro and in vivo at kilovoltage and megavoltage energies is discussed.
Journal ArticleDOI
Cell-specific radiosensitization by gold nanoparticles at megavoltage radiation energies.
Suneil Jain,Jonathan A. Coulter,Alan R. Hounsell,Karl T. Butterworth,Stephen J. McMahon,Wendy B. Hyland,Mark F. Muir,Glenn R. Dickson,Kevin M. Prise,Frederick Currell,Joe M. O'Sullivan,David G. Hirst +11 more
TL;DR: The sensitization was cell-specific with comparable effects at kV and MV energies, no increase in DSB formation, and GNP chemopotentiation with bleomycin, suggesting a possible biological mechanism of radiosensitization.
Journal ArticleDOI
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial.
Joaquin Mateo,Nuria Porta,Diletta Bianchini,Ursula McGovern,Tony Elliott,Robert Jones,Isabel Syndikus,Christy Ralph,Suneil Jain,Mohini Varughese,Omi Parikh,Simon J. Crabb,Angus Robinson,Duncan B. McLaren,A. Birtle,Jacob Tanguay,Susana Miranda,Ines Figueiredo,George Seed,Claudia Bertan,Penny Flohr,Berni Ebbs,Pasquale Rescigno,Gemma Fowler,Ana Ferreira,Ruth Riisnaes,Rita Pereira,Andra Curcean,Robert Chandler,Matthew Clarke,Bora Gurel,Mateus Crespo,Daniel Nava Rodrigues,Shahneen Sandhu,Aude Espinasse,Peter Chatfield,Nina Tunariu,Wei Yuan,Emma Hall,Suzanne Carreira,Johann S. de Bono +40 more
TL;DR: The TOPARP-B trial aims to prospectively validate the association between DDR gene aberrations and response to olaparib in metastatic castration-resistant prostate cancer by recruiting participants from 17 UK hospitals and following follow-up for a period of 24·8 months.